Biomarkers and pharmacoeconomics in rheumatoid arthritis: a good marriage

References

• Dennis G, Jr, Holweg CTJ, Kummerfeld SK, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014;16(2):R90.
   PubMed Web of Science ®Google Scholar
• Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):499–505.
   PubMed Web of Science ®Google Scholar
• Bobbio-Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis. 2007;66(3):302–307.
   PubMed Web of Science ®Google Scholar
• De Rycke L, Verhelst X, Kruithof E, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):299–302.
   PubMed Web of Science ®Google Scholar
• Lv Q, Yin Y, Li X, et al. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFalpha agent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoS One. 2014;9(2):e89442.
   PubMed Web of Science ®Google Scholar
• Chen HA, Lin KC, Chen CH, et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(1):35–39.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Dell’ Acqua D, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther. 2006;8(1):R3.
   PubMed Web of Science ®Google Scholar
• Bos WH, Bartelds GM, Wolbink GJ, et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol. 2008;35:1972–1977.
   PubMed Web of Science ®Google Scholar
• Maneiro RJ, Salgado E, Carmona L, et al. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum. 2013;43(1):9–17.
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Kawakami A, Iwamoto N, et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol. 2011;21(4):370–374.
   PubMed Web of Science ®Google Scholar
• Iwata S, Nakayamada S, Fukuyo S, et al. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. Arthritis Rheumatol. 2015;67(1):63–73.
   PubMed Web of Science ®Google Scholar
• Picchianti Diamanti A, Rosado MM, Scarsella M, et al. Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents. Clin Exp Immunol. 2014;177(3):630–640.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Salvin S, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower dis- ability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology. 2009;48(12):1557–1559.
   PubMed Web of Science ®Google Scholar
• Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, et al. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. PLoS One. 2012;7(7):e40362.
   PubMed Web of Science ®Google Scholar
• Araújo FC, Gonçalves J, Fonseca JE. Biosimilars in rheumatology. Pharmacol Res. 2019;149:104467.
   PubMed Web of Science ®Google Scholar
• Sokolove J, Schiff M, Fleischmann R, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016;75(4):709–714.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Litman HJ, Connolly SE, et al. Comparative effectiveness of abatacept versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis who are Anti-CCP Positive in the United States Corrona Registry. Rheumatol Ther. 2019;6(2):217–230.
   PubMed Web of Science ®Google Scholar
• Yee A, Webb T, Seaman A, et al. Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol Res. 2015;61(1–2):24–30.
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Duryee MJ, England BR, et al. Malondialdehyde-acetaldehyde antibody concentrations in rheumatoid arthritis and other rheumatic conditions. Int Immunopharmacol. 2018;56:113–118.
   PubMed Web of Science ®Google Scholar
• Auger I, Charpin C, Balandraud N, et al. Autoantibodies to PAD4 and BRAF in rheumatoid arthritis. Autoimmun Rev. 2012;11(11):801–803.
   PubMed Web of Science ®Google Scholar
• Seaman A, Darrah E, Infantino M, et al. Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis. Autoimmun Rev. 2016;15(7):776–780.
   PubMed Web of Science ®Google Scholar
• Hirata S, Marotta A, Gui Y, et al. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther. 2015;17:280.
   PubMed Web of Science ®Google Scholar
• Alunno A, Bistoni O, Pratesi F, et al. Anti-citrullinated alpha enolase antibodies, interstitial lung disease and bone erosion in rheumatoid arthritis. Rheumatology (Oxford)). 2018;57(5):850–855.
   PubMed Web of Science ®Google Scholar
• Park SH, Han X, Lobo F, et al. A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis. J Med Econ. 2020. DOI:10.1080/13696998.2020.1732991
   PubMed Web of Science ®Google Scholar
• Best JH, Vlad SC, Pei J. Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis. Rheumatol Ther. 2020;7(1):165–171.
   PubMed Web of Science ®Google Scholar
• Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94.
   PubMed Web of Science ®Google Scholar
• Gaultney J, Benucci M, Iannazzo S, et al. Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy. Expert Rev Pharmacoecon Outcomes Res. 2016;16(3):409–417.
   PubMed Web of Science ®Google Scholar
• Weijers L, Baerwald C, Mennini FS, et al. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada. Rheumatol Int. 2017;37(7):1111–1123.
   PubMed Web of Science ®Google Scholar
• Alemao E, Johal S, Al MJ, et al. Cost-effectiveness analysis of abatacept compared with adalimumab on background methotrexate in biologic-naive adult patients with rheumatoid arthritis and poor prognosis. Value Health. 2018;21(2):193–202.
   PubMed Web of Science ®Google Scholar
• Neubauer AS, Minartz C, Herrmann KH, et al. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept. Clin Exp Rheumatol. 2018;36(3):448–454.
   PubMed Web of Science ®Google Scholar
• Benucci M, Damiani A, Manfredi M, et al. Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life. Clinicoecon Outcomes Res. 2019;11:405–409.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Snedecor SJ, Ektare V, et al. Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. Clinicoecon Outcomes Res. 2017;9:451–458.
   PubMed Web of Science ®Google Scholar
• Benucci M, Cantini F. Non-medical switching: save today and pay tomorrow. J Med Econ. 2019;22(11):1160–1161.
   PubMed Web of Science ®Google Scholar